Oncogene addiction to c-MYC in myeloma cells.
作者信息
Holien Toril, Sundan Anders
出版信息
Oncotarget. 2012 Aug;3(8):739-40. doi: 10.18632/oncotarget.631.
Abstract
摘要
相似文献
1
Oncogene addiction to c-MYC in myeloma cells.骨髓瘤细胞对c-MYC的癌基因成瘾性。
Oncotarget. 2012 Aug;3(8):739-40. doi: 10.18632/oncotarget.631.
2
MYC needs MNT.MYC需要MNT。
Cell Cycle. 2013 Feb 1;12(3):385-6. doi: 10.4161/cc.23551. Epub 2013 Jan 16.
3
Transcriptional regulation. Flipping the Myc switch.转录调控。翻转Myc开关。
Curr Biol. 1995 Aug 1;5(8):859-61. doi: 10.1016/s0960-9822(95)00173-4.
4
Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.靶向 miR-21 的 NL101 阻断了 c-Myc/Mxd1 循环，抑制了 B 细胞淋巴瘤的生长。
Theranostics. 2021 Jan 19;11(7):3439-3451. doi: 10.7150/thno.53561. eCollection 2021.
5
The MYCL and MXD1 transcription factors regulate the fitness of murine dendritic cells.MYCL 和 MXD1 转录因子调节小鼠树突状细胞的适应性。
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4885-4893. doi: 10.1073/pnas.1915060117. Epub 2020 Feb 18.
6
Myc, Max, and Mnt: molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis.Myc、Max和Mnt：胆汁淤积增强胆管癌发生的分子机制
Gastroenterology. 2011 Jul;141(1):32-4. doi: 10.1053/j.gastro.2011.05.022. Epub 2011 May 26.
7
Structural aspects of interactions within the Myc/Max/Mad network.Myc/Max/Mad网络内相互作用的结构方面。
Curr Top Microbiol Immunol. 2006;302:123-43. doi: 10.1007/3-540-32952-8_5.
8
MYC and transcription elongation.MYC 与转录延伸。
Cold Spring Harb Perspect Med. 2014 Jan 1;4(1):a020990. doi: 10.1101/cshperspect.a020990.
9
Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.从小鼠和人肝细胞胆汁淤积期间从Mnt-Max转换为Myc-Max可诱导p53和细胞周期蛋白D1表达以及细胞凋亡。
Hepatology. 2009 Mar;49(3):860-70. doi: 10.1002/hep.22720.
10
Identification of recognition sites for myc/max/mxd network proteins by a whole human chromosome 19 selection strategy.通过全人类19号染色体筛选策略鉴定Myc/Max/Mxd网络蛋白的识别位点
Biochemistry (Mosc). 2008 Nov;73(11):1260-8. doi: 10.1134/s0006297908110138.
引用本文的文献
1
Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.新型双靶点 c-Myc 抑制剂 D347-2761 通过阻断 c-Myc/Max 异二聚体形成和干扰其稳定性抑制骨髓瘤生长。
Cell Commun Signal. 2022 May 26;20(1):73. doi: 10.1186/s12964-022-00868-6.
2
GFI1-Dependent Repression of Increases Multiple Myeloma Cell Survival.GFI1 依赖性抑制作用增强多发性骨髓瘤细胞的存活能力。
Cancers (Basel). 2022 Feb 2;14(3):772. doi: 10.3390/cancers14030772.
3
Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.Wnt/β-连环蛋白信号通路中多发性骨髓瘤风险的遗传决定因素。
Cancer Epidemiol. 2021 Aug;73:101972. doi: 10.1016/j.canep.2021.101972. Epub 2021 Jun 30.
4
Management of Myeloma Bone Lesions.多发性骨髓瘤骨病的治疗。
Int J Mol Sci. 2021 Mar 25;22(7):3389. doi: 10.3390/ijms22073389.
5
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?多发性骨髓瘤的免疫疗法：转化小鼠模型如何提供帮助？
J Oncol. 2019 Apr 10;2019:2186494. doi: 10.1155/2019/2186494. eCollection 2019.
6
Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway.孟鲁司特通过抑制 mTOR 通路增强卡非佐米在多发性骨髓瘤中的细胞毒性作用。
Cancer Biol Ther. 2019;20(3):381-390. doi: 10.1080/15384047.2018.1529112. Epub 2018 Oct 25.
7
Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma.芳基烃受体/多胺生物合成轴的抑制可抑制多发性骨髓瘤。
J Clin Invest. 2018 Oct 1;128(10):4682-4696. doi: 10.1172/JCI70712. Epub 2018 Sep 10.
8
Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells.鉴定一种新型的 c-Myc 抑制剂，对多发性骨髓瘤细胞具有抗肿瘤作用。
Biosci Rep. 2018 Sep 19;38(5). doi: 10.1042/BSR20181027. Print 2018 Oct 31.
9
1,2,3,4,6-Penta--Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression.1,2,3,4,6-五没食子酰-β-D-吡喃葡萄糖苷抑制多发性骨髓瘤细胞增殖并伴随MYC表达受抑制。
Front Pharmacol. 2018 Feb 2;9:65. doi: 10.3389/fphar.2018.00065. eCollection 2018.
10
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.多梳蛋白家族蛋白BMI-1抑制剂PTC-209无论是单独使用还是与靶向EZH2和BET溴结构域的表观遗传抑制剂联合使用，都是一种有效的抗骨髓瘤药物。
Oncotarget. 2017 Oct 20;8(61):103731-103743. doi: 10.18632/oncotarget.21909. eCollection 2017 Nov 28.
本文引用的文献
1
Addiction to c-MYC in multiple myeloma.多发性骨髓瘤中 c-MYC 的成瘾性。
Blood. 2012 Sep 20;120(12):2450-3. doi: 10.1182/blood-2011-08-371567. Epub 2012 Jul 17.
2
Cancer. Taking a back door to target Myc.癌症。通过旁门途径靶向Myc。
Science. 2012 Jan 20;335(6066):293-4. doi: 10.1126/science.1217819.
3
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.在 MYC 抑制后复发的淋巴瘤继续表现出癌基因成瘾。
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17432-7. doi: 10.1073/pnas.1107303108. Epub 2011 Oct 3.
4
Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.骨形态发生蛋白通过 Smad 依赖性抑制 MYC 诱导多发性骨髓瘤细胞凋亡。
Leukemia. 2012 May;26(5):1073-80. doi: 10.1038/leu.2011.263. Epub 2011 Sep 23.
5
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.MYC 激活的临床和生物学意义：MGUS 和新诊断多发性骨髓瘤之间的共同差异。
Leukemia. 2011 Jun;25(6):1026-35. doi: 10.1038/leu.2011.53. Epub 2011 Apr 5.
6
IRF4 addiction in multiple myeloma.多发性骨髓瘤中的IRF4成瘾
Nature. 2008 Jul 10;454(7201):226-31. doi: 10.1038/nature07064. Epub 2008 Jun 22.
7
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.Myc-Max干扰剂10058-F4 [Z,E]-5-[4-乙基亚苄基]-2-硫代噻唑烷-4-酮在小鼠体内的疗效、药代动力学、组织分布及代谢
Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. doi: 10.1007/s00280-008-0774-y. Epub 2008 May 29.
8
Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells.骨形态发生蛋白-5、-6和-7抑制人骨髓瘤细胞生长并诱导其凋亡。
Oncogene. 2004 Apr 15;23(17):3024-32. doi: 10.1038/sj.onc.1207386.
9
Low molecular weight inhibitors of Myc-Max interaction and function.Myc-Max相互作用及功能的低分子量抑制剂
Oncogene. 2003 Sep 18;22(40):6151-9. doi: 10.1038/sj.onc.1206641.
10
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.与多发性骨髓瘤中c-myc失调及肿瘤进展相关的c-myc基因座的多种核型异常。
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33. doi: 10.1073/pnas.97.1.228.
Zotero 插件